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Abstract. – OBJECTIVE: To evaluate the rela-
tionship between body mass index (BMI) and rates 
of treatment tolerance and clinical outcomes in pa-
tients with locally advanced rectal cancer treated 
with a multimodality approach.
PATIENTS AND METHODS: This study was 
conducted on 56 patients with histologically prov-
en rectal adenocarcinoma, staged T3-4, and/or 
node-positive tumor, which underwent intensified 
radiochemotherapy (RT-CHT) treatment before 
surgery. We calculated adiposity indices and ana-
lyzed their influence on treatment tolerance and 
clinical outcomes.
RESULTS: Distribution of the 56 patients ac-
cording to BMI was BMI < 25 kg/m2 (n = 19; 33.9%), 
BMI 25-29 kg/m2 (n = 29; 51.8%) and BMI ≥ 30 kg/m2 
(n = 8; 14.3%). BMI had no significant influence on 
neo-adjuvant treatment-related toxicity. With a 
median follow-up of 23 months (range 11-47), the 
2-year survival was 85.7%. We did not observe any 
significant difference among the three BMI cate-
gories for any of the outcomes.
CONCLUSIONS: This study suggested no evi-
dent links between overweight and survival in pa-
tients with locally advanced rectal carcinoma treat-
ed with neo-adjuvant RT-CHT. Overweight patients 
tolerate treatment as normal-weight patients.
Key Words
Rectal cancer, BMI, Obesity, Radiotherapy, Chemo-
therapy, Surgery.
Introduction
Overweight and obesity are a growing public 
health problem in industrialized countries, as a 
result of a total change in lifestyle based on physi-
cal inactivity and increased fat-rich dietary intake. 
They are typically defined by a high body mass 
index (BMI) and associated with cardiovascular 
and metabolic diseases1. However, epidemiolog-
ical analysis has demonstrated that in 15-45% of 
cases, excess of weight is linked to cancerogene-
sis process in certain cancer types, including rec-
tal carcinoma1,2. The mechanism is still unknown, 
but it seems related to the distribution of body fat, 
particularly in the visceral compartment3,4. In fact 
it has been suggested a relationship between vis-
ceral adiposity and worst oncologic outcome for 
rectal cancer, especially for males5-7. However, 
there are different studies that have not demon-
strated any predictive value on overall mortality 
in overweight and obese patients8,9. Therefore, at 
present, the impact of adiposity remains contro-
versial. The aim of this study is to determine if the 
excess of weight, as measured by conventional 
adiposity indices, can be defined a risk factor for 
post multimodality treatment outcome in locally 
advanced rectal cancer. 
Patients and Methods 
Patient Selection
Data of all patients who received intensified 
neo-adjuvant treatment for locally advanced rec-
tal carcinoma were abstracted from a prospective-
ly maintained rectal database after Institutional 
Review Board Approval. We enrolled patients 
once an informed consent was signed. All patients 
had histologically proven rectal adenocarcinoma, 
clinically staged IIa-IIIc disease (according to the 
7th American Joint Committee on Cancer Staging 
System10). Patients were excluded from the study 
in case of synchronous tumors, cardiovascular 
disease, history of neurological or psychiatric dis-
orders, or previous radiation therapy or chemo-
therapy.
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Adiposity Indices
The measure of excess of weight used was the 
BMI, calculated as weight divided by height squared 
(kg/m2). Pre-treatment BMI was obtained for all pa-
tients. According to the WHO guidelines11, patients 
were classified as normal weight (BMI < 25 kg/m2), 
overweight (BMI 25-29 kg/m2) and obese (BMI ≥ 
30 kg/m2). Considering that BMI does not differen-
tiate between lean mass and adipose tissue, we have 
calculated other quantitative measure of abdominal 
fat compartments to define the obesity in term of vis-
ceral fat. Validating quantitative radiologic measures 
of subcutaneous adipose tissue (SAT) and visceral 
adipose tissue (VAT) volumes were assessed using 
pre-treatment CT scan12,13. A single axial slice at the 
level of L4-L5 intervertebral space was used to mea-
sure SAT and VAT. CT image was set between -195 
to -45 Hounsfield units. The areas of adipose tissue 
were delineated by a physician. SAT was defined as 
the extra-peritoneal fat between the skin and mus-
cles, and VAT as the intra-peritoneal fat. SAT and 
VAT areas were automatically calculated by CT 
software. Visceral fat to subcutaneous fat ratio (V/S) 
was obtained to achieve an additional parameter. A 
ratio of 0.4 was considered the cut-off line to define 
visceral obesity (V/S ≥ 0.4) and subcutaneous adi-
posity (V/S < 0.4)14.
Treatment Plan
All patients were treated with a long course of 
radiochemotherapy (RT-CHT). Radiation therapy 
(RT) was delivered with a 3D-conformational mul-
tiple field technique at a dose of 45 Gy (in 25 daily 
fractions of 1,8 Gy given in 5 weeks) to the whole 
pelvis, plus a 5,4-9 Gy (in 3-5 daily fractions of 
1,8 Gy) to the tumor volume, with 6-15 MV en-
ergy photons. Chemotherapy (CHT) consisted of 
2 h oxaliplatin infusion 50 mg/m2 on the first day 
of each week of radiotherapy and 5 daily continu-
ous infusion of 5-FU 200 mg/m2/die15. The choice 
of adding oxaliplatin to the standard schedule of 
5-FU was dictated by our previous experience, in 
which the addition of oxaliplatin has resulted in a 
high rate of pathological complete response (pCR) 
with acceptable toxicity, although in literature its 
real benefit remains unclear16,17. Treatment-related 
toxicity was recorded by grade according to the 
National Cancer Institute Common Toxicity Crite-
ria for Adverse Events, version 4.0318.
Surgery was planned 7-9 weeks after the end 
of RT-CHT treatment. The type of surgery was 
left to the surgeon’s discretion. The type of ad-
juvant chemotherapy was chosen by the oncolo-
gist. After surgery, all patients were monitored at 
3-month intervals for the first year and at 6-month 
intervals for the subsequent years. 
Statistical Analysis
Baseline characteristics were summarized with 
descriptive statistics. Fisher’s exact tests were used 
to compare discrete variables between groups. Sta-
tistical tests were two-sided. A p-value < 0.05 was 
considered statistically significant in the tests. 
Overall survival (OS) and disease-free survival 
(DFS) were measured in months from the end of 
the neo-adjuvant treatment to the date of death or 
last follow-up. To determine the influence on sur-
vival, the variable BMI and V/S were considered. 
The Kaplan-Meier method was used to estimate the 
survival distribution and comparisons of survival 
between subgroups were made using the long-rank 
test. The relationship between predictive factors 
and survival was assessed using a logistic model in 
multivariate analysis. Statistical analysis was per-
formed using R statistical package.
Results
Between January 2010 and December 2013, 
56 patients underwent intensified neo-adjuvant 
RT-CHT and met the inclusion criteria. The co-
hort included 37 male and 19 female patients with 
a median age of 63.28 years (range 38-76). Pa-
tients characteristics and adiposity measurements 
are shown in Table I. Distribution of the 56 pa-
Table I. Patient characteristics and adiposity measurement.
BMI: body mass index; VAT: visceral adipose tissue; SAT: 
subcutaneous adipose tissue; V/S: visceral fat to subcutaneous 
fat ratio 
Characteristics  N patients (%)
Age, years 
Median (range) 63.28 (38-76) 
Sex 
   Male 37 (66.1)
   Female 19 (33.9)
BMI, kg/m2 
Median (range) 26.35 (14.84-34.94)
< 25 19 (33.9)
25-29 29 (51.8)
≥ 30 8 (14.3)
VAT, cm2 
Median (range) 74.66 (5.20-164.04)
SAT, cm2 
Median (range) 125.425 (16.95-229.26)
V/S 
   < 0.4 7 (12.5)
   ≥ 0.4 49 (87.5)
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tients according to BMI was BMI < 25 kg/m2 (n 
= 19; 33.9%), BMI 25-29 kg/m2 (n = 29; 51.8%) 
and BMI ≥ 30 kg/m2 (n = 8; 14.3%). The median 
BMI, VAT and SAT were 26.35 kg/m2, 74.66 cm2 
and 125.425 cm2, respectively. 
Excess of Weight and Toxicity
We analyzed the influence of excess of weight 
on the rates of the major RT-CHT adverse effects. 
The occurrence of acute toxicity is summarized in 
Table II. Due to the low number of obese patient 
(n = 8), we combined patients with BMI 25-29 
kg/m2 and BMI ≥ 30 kg/m2 and compared them 
to normal weight in the data analyses. Proctitis, 
grade ≤ G2, was the most common symptom 
(69.6%). The occurrence of fatigue (p-value = 
0.866), neutrophils-granulocytes alteration (p = 
0.169) and radiation-dermatitis (p = 0.662) did 
not differ between overweight and normal weight 
patients. Similarly, the occurrence of gastrointes-
tinal symptoms was comparable. We observed a 
higher prevalence of vomiting in normal weight 
patients, but the proportion was not significant-
ly different in the two groups (p = 0.059). Over-
weight patients were less subject to diarrhea grade 
> 2, but this relationship was not significantly (p = 
0.055). Briefly, BMI had no significant influence 
on neo-adjuvant treatment-related toxicity.
Excess of Weight and Sex
In terms of BMI only 14.3% of patients were 
classified as obese. Alternatively, considering the 
BMI: body mass index.
Table II. Acute toxicity.
Toxicity                           % patients (n)
  
 Total BMI < 25  BMI ≥ 25 p-value
Neutrophils-granulocytes    
      ≤ G2 1.9 (1) 5.3 (1) 0 (0) 0.169
      > G2 . . . .
Fatigue    
      ≤ G2 19.6 (11) 21.1 (4) 18.9 (7) 0.866
      > G2 . . . .
Radiation-dermatitis    
      ≤ G2 33.9 (19) 36.8 (7) 32.4 (12) 0.662
      > G2 5.4 (3) 5.3 (1) 5.4 (2) 0.771
Constipation    
      ≤ G2 21.4 (12) 21.1 (4) 21.6 (8) 0.866
      > G2 . . . .
Diarrhea    
      ≤ G2 30.4 (17) 26.3 (5) 32.4 (12) 0.653
      > G2 3.5 (2) 10.5 (2) 0 (0) 0.055
Nausea    
      ≤ G2 14.3 (8) 15.7 (3) 13.5 (5) 0.851
      > G2 . . . .
Proctitis    
      ≤ G2 69.6 (39) 73.7 (14) 67.6 (25) 0.763
      > G2 3.6 (2) 5.3 (1) 2.7 (1) 0.771
Vomiting    
      ≤ G2 7.1 (4) 15.7 (3) 2.7 (1) 0.059
      > G2 . . . .
Neuropathy: sensory    
      ≤ G2 16.1 (9) 15.7 (3) 16.2 (6) 0.851
      > G2 1.8 (1) 0 (0) 2.7 (1) 0.669
Abdominal pain or cramping    
      ≤ G2 10.7 (6) 10.5 (2) 10.8 (4) 0.826
      > G2 1.8 (1) 0 (0) 2.7 (1) 0.669
Dysuria-painful urination    
      ≤ G2 16.1 (9) 21.1 (4) 13.5 (5) 0.358
      > G2 . . . .
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classification of visceral obesity, 87.5% of patients 
had a V/S ≥ 0.4. There was a statistically signif-
icant higher proportion of patients classified as 
obese when using V/S vs. BMI (p ≤ 0.001). There 
was no difference by sex in overweight patients (p 
= 0.06). Any significant survival probability was 
observed when combining sex and visceral adi-
posity (p = 0.884).
Excess of Weight and Outcomes
With a median follow-up of 23 months (range 
11-47) the 2-year survival was 85.7% (Figure 1). 
We did not observe any significant differences 
among the three BMI categories for any of the 
outcomes. Figure 2 shows comparisons of OS 
(Figure 2a) and DFS (Figure 2b) of the patients 
stratified by BMI < 25 kg/m2, 25-29 kg/m2 and 
BMI ≥ 30 kg/m2. There was no statistically signif-
icant difference in OS or DFS in patients stratified 
by BMI (p = 0.792 and 0.807, respectively). Fig-
ure 3 illustrates the comparisons of OS and DFS 
between patients stratified by BMI < 25 vs. BMI ≥ 
25 (Figure 3a-b) and BMI < 30 vs. BMI ≥ 30 (Fig-
ure 3c-d). Again, there was no statistically signif-
icant difference in OS and DFS between patients 
with BMI < 25 vs. BMI ≥ 25 (p = 0.582 and 0.571, 
respectively) or BMI < 30 vs. ≥ 30 (p = 0.829 and 
0.882, respectively). OS and DFS did not differ by 
obesity when defined by V/S measure (p = 0.235 
and 0.185, respectively) (Figure 3).
Multivariate Analysis
Multivariate analysis was performed to iden-
tify independent prognostic factors for OS and 
DFS. The variables entered into the equation were 
age, gender, BMI, clinical stage, tumor localiza-
tion and pCR. None were associated with OS or 
DFS (p ≥ 0.05).
Discussion
In the last few years, the impact of the ex-
cess of weight on cancer-related outcomes has 
become a critical issue. The current analysis rep-
resents an initial attempt to examine the effect of 
adiposity indices on toxicity occurrence and OS 
and DFS in rectal cancer patients treated with a 
long course of intensified RT-CHT followed by 
surgery. Whereas the association between obe-
sity and colon cancer has been well studied19,20, 
only a few studies have evaluated the role that 
obesity plays in the outcomes of rectal can-
cer8,21,22. This is the first comparison of general 
and visceral obesity as predictors of pre-opera-
tive RT-CHT-related toxicity and survival out-
comes in locally advanced rectal cancer. Our 
analysis indicates that treatment-related toxicity 
was not related to excess of weight. In general, 
gastrointestinal toxicity was the most common 
side effect and it was classified as grade > 2 in 
4 patients only. No severe hematological and 
renal toxicity were seen. When comparing nor-
Figure 1. Overall survival of patients undergoing radio-
chemotherapy followed by surgery for locally advanced rec-
tal cancer.
Figure 2. Overall survival (A) and disease free survival (B) in patients stratified by BMI < 25 kg/m2, 25-29 kg/m2 and BMI 
≥ 30 kg/m2.
A B
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mal-weight patients with overweight patients, 
we did not obtain any significant level of toxici-
ty. Studies of rectal neo-adjuvant treatment have 
not analyzed RT-CHT complications in visceral-
ly obese patients21. Meyerhardt et al8, using data 
from a randomized trial of adjuvant RT-CHT in 
patients with stage II-III rectal cancer, found that 
obesity was associated with less treatment-relat-
ed toxicity during RT-CHT. However, RT-CHT 
was performed after surgery, and we were un-
able to evaluate peri- and post- operative com-
plications on the influence of adjuvant treatment 
toxicities. In literature, more data are available 
concerning the association between BMI and sur-
vival outcomes, but the results are often conflict-
ing5,8,19,21-24; thus, it is difficult to compare them. 
In some publications of rectal surgery8,19,24 no dif-
ferences in OS were reached comparing survival 
between obese and non-obese groups; in others, 
high BMI and V/S values were associated with 
prolonged OS22, whereas in others with poorer 
outcome23. This disparity in findings could be 
attributed to heterogeneity of samples (several 
studies reported colon and rectal cancer cases as 
a single cohort), as well as low statistical signif-
icant of studies and different measurable param-
eters using as surrogate of visceral adiposity. We 
also examined whether BMI and V/S were asso-
ciated with survival. Independently of adiposity 
index given, overweight and obesity do not con-
tribute to clinical outcomes. BMI and V/S were 
not demonstrated to be independent factors of 
decreased survival. Although statistical analysis 
failed to detect any differences, V/S was shown 
to have a less pronounced impact than BMI in 
both OS (p = 0.235 vs. 0.792) and DFS (p = 0.185 
Figure 3. Comparisons of OS and DFS between patients stratified by BMI < 25 vs. BMI ≥ 25 (A-B) and BMI < 30 vs. BMI ≥ 30 
(C-D) V/S measure (E-F).
A
C
E
B
D
F
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vs. 0.807). This means that V/S rather than whole 
body adipose tissue should be a risk factor for 
outcome after multimodality treatment in locally 
advanced rectal cancer. A similar trend towards 
worse OS and DFS among those patients with V/S 
≥ 0.4 was also observed in Clark et al21 analysis. 
In a population of 99 rectal cancer patients, they 
reported a shorter DFS (p = 0.04) and a worse OS 
(p = 0.14) in viscerally obese patients than those 
observed in patients with V/S < 0.4. This study is 
limited by its relatively small number of patients; 
therefore, the analysis of subgroup may prove 
not to be statistically significant simply because 
the study has insufficient ability to demonstrate 
real differences. However, well-defined inclusion 
criteria help to minimize bias. Follow-up time is 
relatively short to achieve safe conclusions about 
survival outcomes. The principal finding of this 
data analysis was that the majority of patients 
(66.1%) were overweight or obese. The absence 
of tumor-related cachexia could explain the lack 
of association between obesity and mortality. 
However, follow-up time is substantially adequate 
to detect differences in RT-CHT toxicity. Toxicity 
data were recorded at the time of patient presen-
tation in a standardized manner to ensure quality 
and they were correlated with toxicity grading to 
reduce the rate of underreported events. Despite 
the reduced statistical power to examine the effect 
of intensified neo-adjuvant RT-CHT regime on 
outcome, our toxicity results suggest that the full-
dose of CHT should be calculated on patient actu-
al body weight, including overweight and obese. 
This study requires confirmation by larger cohort 
to account for his potential findings. V/S, rather 
than BMI, seems to be a possible prognostic fac-
tor. Considering that toxicity analysis has shown 
that intensified neo-adjuvant RT-CHT is well tol-
erated, overweight patients should be exposed to 
the same CHT dose calculation received by nor-
mal weight patients. Future studies on this topic 
may help to improve outcomes in overweight lo-
cally advanced rectal cancer patients.
Conclusions
Our data revealed no correlation between adi-
posity indices, both BMI and V/S, and oncologic 
outcomes in patients with locally advanced rec-
tal carcinoma treated with neo-adjuvant RT-CHT. 
Patients with excess of weight well tolerate inten-
sified pre-operative treatment as normal weight 
patients.
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